Skip to content

Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.

by Tatsuya Katayama, Junichi Shimizu, Kenichi Suda, Ryoichi Onozato, Takayuki Fukui, Simon Ito, Shunzo Hatooka, Taijiro Sueda, Toyoaki Hida, Yasushi Yatabe, Tetsuya Mitsudomi show all authors
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer ()
Get full text at journal


INTRODUCTION: The efficacy of high-dose (1250 mg/d) gefitinib for the treatment of leptomeningeal metastasis in a patient with lung cancer harboring a mutation in the epidermal growth factor receptor (EGFR) gene was previously reported. We speculate that erlotinib, instead of high dose of gefitinib, may be also effective for the treatment of central nervous system (CNS) lesions, as trough serum concentration of erlotinib is nine times higher than that of gefitinib.\n\nPATIENTS AND METHODS: Patients with lung cancer in whom CNS lesions developed after an initial good response to gefitinib for extra CNS lesions were enrolled in the study. Tumor response, performance status, neurologic symptoms, and survival were retrospectively evaluated.\n\nRESULTS: All seven patients had EGFR mutations in their primary tumors except one patient. The median interval between gefitinib withdrawal and erlotinib administration was 5 days. Three patients showed partial response, three had stable disease, and one had progressive disease. Performance status and symptoms improved in five patients. The overall survival from the initiation of erlotinib treatment ranged from 15 to 530 days (median, 88 days).\n\nCONCLUSIONS: Erlotinib was a reasonable option for the treatment of CNS diseases that appeared after a good initial response of extra CNS disease to gefitinib.

Cite this document (BETA)

Authors on Mendeley

Readership Statistics

33 Readers on Mendeley
by Discipline
73% Medicine and Dentistry
9% Agricultural and Biological Sciences
6% Pharmacology, Toxicology and Pharmaceutical Science
by Academic Status
39% Researcher
15% Other
15% Student > Ph. D. Student
by Country
3% Japan

Sign up today - FREE

Mendeley saves you time finding and organizing research. Learn more

  • All your research in one place
  • Add and import papers easily
  • Access it anywhere, anytime

Start using Mendeley in seconds!

Sign up & Download

Already have an account? Sign in